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Available online 18 January 2016Eukaryotic elongation factor 2 kinase (eEF2K) inhibits the elongation stage of protein synthesis by phosphorylat-
ing its only known substrate, eEF2. eEF2K is tightly regulated by nutrient-sensitive signalling pathways. For ex-
ample, it is inhibited by signalling through mammalian target of rapamycin complex 1 (mTORC1). It is
therefore activated under conditions of nutrient deﬁciency.
Here we show that inhibiting eEF2K or knocking down its expression renders cancer cells sensitive to death
under nutrient-starved conditions, and that this is rescued by compounds that block protein synthesis. This im-
plies that eEF2K protects nutrient-deprived cells by inhibiting protein synthesis. Cells inwhich signalling through
mTORC1 is highly active are very sensitive to nutrient withdrawal. Inhibiting mTORC1 protects them. Our data
reveal that eEF2K makes a substantial contribution to the cytoprotective effect of mTORC1 inhibition.
eEF2K is also reported to promote another potentially cytoprotective process, autophagy. We have used several
approaches to testwhether inhibition or loss of eEF2K affects autophagy under a variety of conditions.Weﬁndno
evidence that eEF2K is involved in the activation of autophagy in the cell types we have studied.
We conclude that eEF2K protects cancer cells against nutrient starvation by inhibiting protein synthesis rather
than by activating autophagy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Glucose starvation1. Introduction
Recent work has identiﬁed eukaryotic elongation factor 2 kinase
(eEF2K) as playing a key cytoprotective role in cancer cells under condi-
tions of nutrient starvation [1], implying that inhibiting its activity may
offer a novel therapeutic avenue in oncology.With this inmind, it is cru-
cial to understand how eEF2K exerts this cytoprotective function.
eEF2K phosphorylates and inactivates eEF2, the protein required to
help move the ribosome along the mRNA during translation elongation
[2]. eEF2K belongs to a small group of atypical protein kinases, termed
α-kinases [3]. To date, eEF2 is the only protein, other than eEF2K itself
[4,5], that is known to be phosphorylated by eEF2K. Protein synthesis
consumes a large amount of energy [6], almost all (N99%) of it in the
elongation process. Elongation also uses almost all the amino acidses, University of Southampton,
Proud).
Building, Southampton General
Kingdom.
. This is an open access article underconsumed by protein synthesis. Consistent with this, the activity of
eEF2K and the phosphorylation of eEF2 are increased under conditions
of energy depletion or amino acid starvation [1,2,7].
Energy depletion (such as starvation of cells for glucose) can activate
eEF2K via the AMP-activated protein kinase, AMPK [7], while amino
acid starvation causes the inhibition of signalling through mammalian
target of rapamycin complex 1 (mTORC1), a negative regulator of
eEF2K. As noted, recent data show that eEF2K is important for the ability
of cancer cells to withstand nutrient deprivation [1], and promotes
breast cancer [8]. These recent discoveriesmaymean that eEF2K is a po-
tential target for therapeutic intervention to tackle poorly-vascularised
solid tumours. Since eEF2K slows down the elongation stage of mRNA
translation, eEF2K may protect nutrient-deprived cells by decreasing
the demands of protein synthesis for nutrients and energy.
Autophagy is a degradative process which can also protect cells
during nutrient starvation and, like eEF2K, is negatively regulated by
mTORC1 signalling [9]. Autophagy can break down macromolecules
into their component building blocks and may therefore help cells to
withstand periods of amino acid starvation. Activation of AMPK can
also promote autophagy, likely by phosphorylating ULK1, an upstreamthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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through the mammalian target of rapamycin complex 1 (mTORC1)
also regulates autophagy, in that case to restrain it [9]. Several studies
have suggested that eEF2K may regulate (promote) autophagy in glio-
ma cells [15–17] or mouse embryonic ﬁbroblasts [18], such that it
might provide a link between mTORC1 signalling and the regulation of
autophagy. Dysregulation of autophagy is one of the hallmarks of can-
cer, although the role of autophagy in cancer is complex [19]. Autophagy
may hinder tumorigenesis initially, but subsequently aid the survival of
cancer cells in established tumours [19,20]. However, no mechanism
has so far been identiﬁed to explain how eEF2K could control
autophagy.
The emerging data which show that eEF2K protects cancer cells
against nutrient deprivation prompted us to examine how it exerts
these cytoprotective effects. Our data provide strong evidence that
eEF2K does so by inhibiting protein synthesis, and do not support the
idea that eEF2K regulates autophagy, at least in the cell types we have
studied. These ﬁndings are particularly important given the growing in-
terest in eEF2K as a target for cancer therapy.
2. Experimental
2.1. Materials
Bradford assay reagent (500–-0001) was from Bio-Rad. Com-
pounds JAN-384, -452, -613 and -849 were kindly provided Janssen
Pharmaceutica NV (Beerse, Belgium). The properties of JAN-384
and the much less active analogue JAN-452 are described in [21].
JAN-613 is inactive against in vitro eEF2K at 30 μM; it was not tested
against other kinases. JAN-849 was tested in a 234-kinase panel at
Millipore, with following results (IC50): eEF2K, 16 nM; CLK2,
109 nM; GSK3α, 126 nM; GSK3β, 132 nM; CDK7, 269 nM; CDK9,
333 nM; all other kinases N1000 nM. A patent covering these com-
pounds was published in 2015 (WIPO Patent Application WO/
2015/150557).
Signalling inhibitors and other compounds were obtained as fol-
lows: rapamycin (553211), Calbiochem; AZD8055 (S1555), MK2206
(S1078) and MG132 (S2619), Selleck; cycloheximide (CHX) (01810),
Harringtonine (19079), chloroquine (C6628) and baﬁlomycin A1
(B1793), Sigma-Aldrich.
Primary antibodies: the P-eEF2 Thr56 antisera were custommade
by Eurogentec (Belgium). Anti-eEF2K antibody was kindly provided
by the Division of Signal Transduction Therapy, College of Life Sci-
ences, University of Dundee, UK. Other antibodies were obtained as
follows: eEF2 (catalogue number 2332), P-protein kinase B (PKB,
also termed Akt, Ser473, 4060), P-ribosomal protein S6 240/244
(5364), LC3A/B (12741), poly ADP-ribose polymerase (PARP,
5625), all from Cell Signalling Technology; GAPDH (G8795), actin
(A5441) and glutathione S-transferase (GST, GE27-4577-01) from
Sigma-Aldrich.
2.2. Cell culture, transfection and treatment
Mouse embryonic ﬁbroblasts (MEFs) from eEF2K−/− (knockout)
mice and matched wild-type counterparts were prepared from embry-
os at embryonic day 13.5. MEFs from eEF2K (WT) and eEF2K−/−mouse
embryos were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM
(41966); Invitrogen) supplemented with 10% foetal bovine serum (FBS,
F2442, Sigma-Aldrich), 100 units/mL penicillin and 0.1 mg/mL strepto-
mycin (15140–122, Invitrogen) at 37 °C in a humidiﬁed atmosphere of
5% CO2. Immortalised TSC2−/−MEFs were generously provided by Dr.
David Kwiatkowski (Harvard University, Boston). Human colon carci-
noma HCT116 cell lines were cultured using standard procedures in a
humidiﬁed incubator at 37 °Cwith 5% CO2 inMcCoy's 5Amedia supple-
mented with 10% (v/v) FBS, 1.5 mM glutamine (25,030–081, Gibco),
100 units/mL penicillin and 0.1 mg/mL streptomycin. Human lungcarcinoma A549 cell line containing an inducible shRNA plasmid direct-
ed towards the eEF2K mRNA was generously provided by Janssen
Pharmaceutica NV and cells were cultured using standard procedures
in a humidiﬁed incubator at 37 °C with 5% CO2 in DMEMmedia supple-
mented with 10% (v/v) FBS, 1.5 mM glutamine (25030-081, Gibco),
100 units/mL penicillin and 0.1 mg/mL streptomycin. To induce
knockdown of eEF2K, cells were cultured for 5 days with 1 mM isopro-
pyl β-D-1-thiogalactopyranoside (IPTG, I6758, Sigma-Aldrich) prior to
experimentation.
After treatment, cells were lysed in ice-cold lysis buffer contain-
ing 1% (v/v) Triton X-100 (215680010, Acros Organics), 50 mM Tris
(T6066-1KG, Sigma-Aldrich)–HCl (258148-2.5 L, Sigma-Aldrich)
pH 7.4, 50 mM NaCl (BP358-212, Fisher Scientiﬁc), 0.2 mM EDTA
(BP120-500, Fisher Scientiﬁc), 0.2 mM EGTA (E1102, Melford),
50 mM β-glycerophosphate (G9422, Sigma-Aldrich), 1 mM Na3VO4
(S6508, Sigma-Aldrich), 15 mM β-mercaptoethanol (125472500,
Acros Organics) and 1× protease inhibitor cocktail (5056489001,
Roche). Lysates were spun at 16,000 ×g for 10 min at 4 °C; the super-
natants were kept and total protein concentration was quantiﬁed by
Bradford assay following the manufacturer's instructions.
2.3. SDS-PAGE and western blot analysis
These procedures were performed as described previously [22].
2.4. BHMT cleavage assay
A549 cells were transfected using lipofectamine LTX (15338100, Life
Technologies) with a GST- betaine homocysteine methyltransferase
(BHMT) reporter vector (kindly provided by Carol Mercer, University
of Cincinnati, USA). 48 h after transfection cells were treated with
AZD8055 (1 μM) for 16 h in the presence of E64d (6 μM, E8640,
Sigma-Aldrich) and leupeptin (11 μM, L9783, Sigma-Aldrich). Cells
were lysed as above. Total protein concentration was determined by
Bradford assay and GST-BHMT was isolated using glutathione-
sepharose (GE17-0756-01, Sigma-Aldrich). The precipitated GST-
BHMT was washed three times in the ice cold lysis buffer. Precipitates
were then boiled in SDS-PAGE sample buffer, resolved by SDS-PAGE
and analysed by western blotting using anti-GST antibody.
2.5. Cell survival
Caspase 3/7 assays (G8090, Promega) were performed according to
the manufacturer's instructions. Brieﬂy, 10,000 cells/well were plated
overnight in a 96-well plate. Cellswere treated as described in theﬁgure
legends for the indicated time period. To measure caspase 3/7 activity,
50 μL of caspase Glo 3/7 reagent was added to each well for 2 h with
constant shaking at room temperature. Luminescence was measured
using a BMG Labtech FLUOstar Optimi plate reader. Cytotoxicity was
evaluated by CellTox Green® cytotoxicity assay (Promega). Brieﬂy,
10,000 cells/well were plated overnight in a 96-well plate. Cells were
treated as described in the ﬁgure legends for the indicated time period.
CellTox green dye was diluted 1/500 in test media and applied to cells
for the times indicated in the ﬁgure. Fluorescence was measured at
485–500 nmEx/520–530 nmEm using a BMG Labtech FLUOstar Optimi
plate reader.
2.6. Autophagic ﬂux analysis
A549 cells were transfected with a vector encoding mCherry-
EGFP-LC3B, a tandem ﬂuorescent-tagged LC3 (a kind gift from Dr.
Terje Johansen, Biochemistry Department, Institute of Medical Biolo-
gy, University of Tromsø, Norway), using lipofectamine 3000
(L3000001, Life technologies) followingmanufacturer's instructions.
After treatment cells were washed twice in phosphate buffered sa-
line (PBS, 18912-014, Gibco) and then ﬁxed in 4% formaldehyde
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PBS and permeabilized with 0.1% Triton-X 100 for 5 min. Cells were
then again washed thrice in PBS and mounted in ProLong® GoldAntifadeMountant (P36935, Life technologies). Cells were visualized
using Leica TCS SP8X/MP microscope equipped with a tuneable
white light laser using a 40× oil immersion objective lens (NA =
287C.E.J. Moore et al. / Cellular Signalling 28 (2016) 284–2931.30) numerical aperture objective. Green/red ﬂuorescence ratio
(GFP loss upon autolysosome formation) was measured using the
Leica Application Suite X (LAS X) software (version 1.1.0).
2.7. Statistical analysis
All data were analysed by performing a two-way ANOVA with
Tukey's multiple comparisons test for signiﬁcance and, for the autopha-
gic ﬂux analysis, a two-way ANOVA with Dunnet's multiple compari-
sons test, using GraphPAD Prism 6 software. All experiments were
performed at least three times with similar results.
3. Results
3.1. eEF2K is cytoprotective for cells faced with glucose starvation
The compounds previously reported as inhibiting eEF2K are ei-
ther highly non-selective (and can even increase eEF2 phosphoryla-
tion [23,24]) or lack potency [24]. Janssen Pharmaceutica NV have
recently developed a small set of highly speciﬁc and potent small-
molecule inhibitors of eEF2K, together with closely-related but
much less potent negative control compounds [25]. We made use
of one such inhibitor (JAN-849) to explore the role of eEF2K in the
ability of colorectal cancer (HCT116) cells to withstand deprivation
for glucose, an important fuel for generating energy. As shown in
Fig. 1A, starving HCT116 cells for glucose caused a modest, but
consistent, increase in the phosphorylation of eEF2, indicative of
activation of eEF2K. This may well be a consequence of the activation
of the AMP-activated protein kinase, AMPK, which showed increased
phosphorylation on its ‘T-loop’ (Thr172; Fig. 1A) in glucose-starved
cells. AMPK is a positive regulator of eEF2K activity [7,26] and
generally acts to damp down energy-consuming processes in times
of energy deﬁciency [27]. Under these conditions, glucose starvation
only had a small effect on cell survival, as judged by the cleavage
of poly ADP-ribose polymerase, PARP (Fig. 1A) and by caspase 3/7 ac-
tivity (Fig. 1B). This clearly indicates that HCT116 cells possess a
mechanism(s) to allow them to withstand glucose starvation.
We asked whether eEF2K played a role in this defence mechanism.
Treating cells with the eEF2K inhibitor JAN-849 decreased eEF2 phos-
phorylation in glucose-starved cells (Fig. 1A), conﬁrming the efﬁcacy
of JAN-849, while a less potent analogue, JAN-452, had almost no effect
on eEF2 phosphorylation, consistent with its weak effect on eEF2K ac-
tivity in vitro. Strikingly, treatmentwith the compound JAN-849 caused
a marked enhancement of markers of cell death, i.e., PARP cleavage and
the activity of caspases 3/7 (Fig. 1A, B) compared to cells starved of glu-
cose in the absence of the inhibitor. JAN-849 only had a small effect on
the survival of glucose-fed cells (Fig. 1B). These data strongly support
the concept that eEF2K is cytoprotective in those nutrient-deprived can-
cer cells.
To assess whether the inhibition of eEF2K promotes cell death by
disinhibiting translation elongation, we explored the effect of re-
imposing inhibition of protein synthesis using two distinct translation
inhibitors, cycloheximide (CHX, which inhibits elongation) and
Harringtonine (Harr, which inhibits a late step in translation initiationFig. 1. eEF2Khelps cellswithstand glucose starvation. (A) HCT116 cellswere either kept in norm
the absence or presence of JAN-452 or−849 (3 μM). Cells were then lysed and samples containi
Values given below each lane show quantitation of the signal for P-eEF2, corrected for the eE
mean ± SEM (control cells without treatment =1; n = 3). (B) HCT116 cells were either kept
for 48 h in the absence or presence of JAN-384 and either cycloheximide (CHX; 5 μg/mL) or H
Data are presented as means ± SEM (n = 3) ****, P b 0.001 for the indicated pairs of conditi
immunoblot analysis using the indicated antibodies. (D) A549 cells were cultured in the pres
were either kept in normal medium containing glucose or transferred to medium lacking glu
added to maintain eEF2K knockdown where indicated. Cell death was measured using CellT
without treatment =1; n = 3). (E) As (D), except cells were cultured for 24 h.[28,29]). Each of these compounds restored cell survival in cells that
had been starved of glucose and treated with the eEF2K inhibitor JAN-
849 (Fig. 1B, C), presumably by inhibiting protein synthesis. It was im-
portant to assess whether these compounds were protecting cells by
enhancing the phosphorylation of eEF2. As shown in Fig. 1C,
Harringtonine had no effect on eEF2 phosphorylation and very little
on mTORC1 signalling, while CHX actually caused a modest decrease
in p-eEF2 again in line with its ability to activate mTORC1 signalling
and enhance S6 phosphorylation [30], although other explanations are
possible (see below). Taken together, these data provide strong evi-
dence that JAN-849 does not promote cell death due to toxicity but rath-
er by alleviating the inhibition of protein synthesis which is normally
imposed by eEF2K in glucose-starved cells.
Thus, eEF2K protects cells against nutrient withdrawal by inhibiting
protein synthesis. These data extend earlier observations where
knocking down eEF2 was shown to help protect cells against nutrient
starvation [1] by demonstrating directly that it is eEF2K's role in regulat-
ing the rate of protein synthesis that underlies its protective ability.
We considered it important to extend our study to other tumour-
related cell lines. A line of A549 lung carcinoma cells harbouring an
IPTG-inducible shRNA against the EEF2K mRNA was developed. The
ability of A549 cells to withstand glucose starvation was decreased
by knocking down eEF2K (Fig. 1D). To assess whether the role of
eEF2K in aiding cell survival was due to inhibition of translation
elongation, we tested the effect of CHX. If eEF2K protects cells by
inhibiting elongation, adding CHX to cells in which eEF2K had been
knocked down should help cell survival. As shown in Fig. 1D, CHX
partially rescued the death induced by glucose starvation, suggesting
that eEF2K does aid cell survival by inhibiting translation elongation.
CHX caused a decrease in eEF2 phosphorylation again (Fig. 1E), consistent
with its ability to activatemTORC1 signalling [30]. The fact that CHX treat-
ment also decreased the levels of eEF2K (Fig. 1E) likely also contributes to
the fall in eEF2 phosphorylation (Fig. 1E). The partial nature of the ‘rescue’
by CHX likely reﬂects the fact that CHX had an adverse effect on cell sur-
vival under control conditions (Fig. 1E), so that the overall level of cell sur-
vival is a ‘trade-off’ between the pro-survival and pro-death effects of this
drug. Starvation for glucose induced the modiﬁcation of LC3 but this was
not impaired in cells where eEF2K had been knocked down (Fig. 1E).
These data indicate that eEF2K promotes cell survival by inhibiting
protein synthesis, consistent with it acting through its only known sub-
strate, eEF2. However, several studies using other cancer cell lines have
reported that eEF2K promotes autophagy and thereby aids cell survival
during nutrient starvation [15–18].3.2. eEF2K does not regulate autophagy in lung carcinoma cells
In A549 cells, 2-DG, rapamycin, the mTOR kinase inhibitor
AZD8055 [31] and the proteasome inhibitor MG132 all induced the
phosphorylation of eEF2, indicative of activation of eEF2K (Fig. 2A).
As shown, IPTG induced reductions in eEF2 phosphorylation and
eEF2K levels in A549 cells (Fig. 2A). However, the ability of each of
these treatments to induce the modiﬁcation of LC3 was not signiﬁ-
cantly diminished by knocking down eEF2K expression (Fig. 2A); in
fact, a slight increase was sometimes observed. (LC3 is modiﬁed byalmediumcontaining glucose or transferred tomedium lacking glucose (−Glc) for 24 h in
ng equal amounts of proteinwere analysed bywestern blot using the indicated antibodies.
F2 signal from multiple experiments as in (A) expressed as P-eEF2 normalized to eEF2,
in normal medium containing glucose or transferred to medium lacking glucose (−Glc)
arringtonine (HARR 2 μg/mL). Cells were lysed and caspase 3/7 activity was determined.
ons. (C) As panel B, except cells were treated for 24 h and cell lysates were subjected to
ence or absence of 1 mM IPTG for 5 days to induce the knockdown of eEF2K. A549 cells
cose (−Glc) for 48 h in the absence or presence of cycloheximide (5 μg/mL). IPTG was
ox Green® assay. Data are expressed relative to the control, mean ± SEM (control cells
288 C.E.J. Moore et al. / Cellular Signalling 28 (2016) 284–293addition of ethanolamine as a key step in autophagosome formation
[32], which causes it to migrate faster on SDS-PAGE indicating stim-
ulation of this step in autophagy).In the presence of chloroquine (CQ), to block autophagy down-
stream of LC3 modiﬁcation, we also observed no difference in the
extent of LC3 modiﬁcation between A549 cells where eEF2K had
289C.E.J. Moore et al. / Cellular Signalling 28 (2016) 284–293been knocked down and corresponding control cells (Supplementa-
ry Fig. S1A, B); CQ increased modiﬁed LC3 to similar extents in all
cases.
To further examine the role of eEF2K in regulating autophagy, A549
cells were treated with the eEF2K inhibitor (JAN-384). Inhibiting eEF2K
activity using JAN-384 increased the levels of LC3II in response tomTOR
inhibition using AZD8055 and rapamycin (Supplementary Fig. S2A, C.
Interestingly autophagy induction by 2-DG was reduced in eEF2K
inhibitor-treated cells although this was not signiﬁcant.
Taken together, these data indicate that eEF2K plays no role in
linking (inhibition of) mTORC1 signalling to the control of autophagy,
as assessed by the levels of modiﬁed LC3.
3.3. eEF2K does not regulate autophagic ﬂux
A number of reservations have been expressed about reliance on
the modiﬁcation of LC3 as a read-out for regulation of autophagy; for
example, its modiﬁcation is an intermediate step in the pathway, not
an endpoint [33]. We therefore used an alternative assay looking for
a product of autophagy, i.e., the cleavage of BHMT. BHMT is a sub-
strate for the autophagic pathway and an assay for this has been de-
veloped using glutathione S-transferase (GST)-tagged BHMT [34].
The degree of cleavage of GST-BHMT gives an end-point readout of
autophagic ﬂux. Treating A549 cells with AZD8055 caused a marked
increase in the phosphorylation of eEF2 and in cleavage of GST-
BHMT (Fig. 2B). IPTG-induced knock down of eEF2K entirely elimi-
nated the phosphorylation of eEF2 but did not prevent the cleavage
of GST-BHMT; if anything, cleavage tended to be greater in the
eEF2K knock-down cells. Cleavage of GST-BHMT was completely
blocked by chloroquine indicating it is entirely due to autophagy,
and no other proteolytic pathways contribute to this (data not
shown). Thus, eEF2K is not required for the process of autophagy
or its activation, at least downstream of mTOR.
We also examined the progression of autolysosome formation
using a tandem ﬂuorescently-tagged LC3 (mCherry-EGFP-LC3B)
which allowed us to determine autophagosome and lysosome fusion
by evaluating loss of GFP ﬂuorescence. Green (GFP) but not red
(mCherry) ﬂuorescence is quenched by protonation in response to
acidiﬁed intra-lysosomal pH upon autolysosome fusion [27]. 33 h
after mCherry-EGFP-LC3B transfection, either vehicle control or the
mTOR inhibitor AZD8055 was added to A549 cells for 16 h to evoke
eEF2K activation as well as inducing autophagy (Fig. 2C), at the end
of the 16 h incubation period (Supplemental Fig. S3), baﬁlomycin
A1 (BafA1) was also added to the cells for 4 h to inhibit the fusion be-
tween autophagosomes and lysosomes and hence preventing the
maturation of autophagic vacuoles. Upon releasing from the block-
age of autolysome production in response to BafA1, there was a grad-
ual decrease in green/red ratio within the next 3 h in vehicle treated
A549 cells, indicative of the re-formation of autolysosomes, whereas
in AZD8055 treated cells, green/red ratio remained low in compari-
son to the control cells, indicating an induction of autophagy and
hence increased autolysosome formation (Fig. 2C, D). AlthoughFig. 2. eEF2K does not regulate autophagy in lung carcinoma cells (A) A549 cells were cultured i
were then treatedwith 10mM2-deoxyglucose (2DG), rapamycin (100 nM), AZD8055 (1 μM) o
protein were analysed by western blot using the indicated antibodies. Values given below each
experiments as in (A) expressed as LC3II normalized to actin,mean±SEM(control cellswithou
A549 cellswere transiently transfectedwith theGST-BHMT construct andmaintained in fullme
E64d. GST-BHMTwas precipitatedwith glutathione agarose from thewhole cell extracts (bottom
(B) expressed as the level of BHMT fragment normalized to the control without IPTG, mean ±
quantitation of the signal for P-eEF2, corrected for the eEF2 signal from multiple experiment
treatment =1; n = 3). (C) Cells were treated as described in Supplemental Fig. S3, visualized
according to green/red ﬂuorescence ratio which reﬂect the percentage of unfused LC3. Scale
***P b 0.001, obtained by two-way ANOVA (Dunnett's test). (E) Untransfected A549 cells we
and 3 h for immunoblotting analysis. Values given below each lane show quantitation o
(E) expressed as LC3II normalized to LC3I, mean ± SEM (control cells without treatment =1;LC3II/I ratio basal levels were high in these cells, AZD8055 was still
capable to further increase the LC3II/I ratio (Fig. 2E), suggesting an
induction of autophagy. Nevertheless, the increase in autolysosome
formation as a result of AZD8055 treatment of A549 cells was not
affected by knocking down eEF2K upon the induction of shRNA in re-
sponse to IPTG treatment (Fig. 2C, D), suggesting that eEF2K does not
play role in the formation of autolysosomes under these conditions.3.4. Activation of autophagy by different stimuli is not impaired in eEF2K-
knock-out MEFs
In viewof earlierﬁndings, largely from glioma cells, we considered it
important to assess whether eEF2K played a role in regulating autopha-
gy in other cell types and situations. We exploited the availability of
cells (embryonic ﬁbroblasts) from mice in which the eEF2K gene has
been disrupted (termed eEF2K−/− (KO) MEFs). As expected, both the
expression of eEF2K and the phosphorylation of eEF2 are lost in MEFs
from eEF2K−/− mice (Fig. 3A). Wild-type (WT) or eEF2K−/− MEFs
were treated in ways previously shown to activate autophagy,
i.e., addition of the PKB/Akt inhibitor MK2206 [35], starvation for glu-
cose or exposure to 2-deoxyglucose (2-DG), a metabolic ‘poison’
which causes depletion of ATP levels. Each of these treatments in-
creased the level of phosphorylation of eEF2 in WT MEFs, with 2-DG
having the greatest effect (Fig. 3A). The various treatments of WT
MEFs caused a shift in the ratio of the two forms of LC3 from the
upper (LC3I) to the lower band (LC3II, Fig. 3A). The effects of these con-
ditions on LC3 were at least as marked in eEF2K−/−MEFs as inWT cells
(Fig. 3A; data are quantiﬁed for replicate experiments in Fig. 3B). These
data indicate that eEF2K function is not required for the induction of au-
tophagy under any of these conditions, in line with earlier ﬁndings for
nutrient-deprived MEFs [1].
Since it is well established that mTORC1 signalling negatively reg-
ulates both autophagy and eEF2K, we studied whether eEF2K is in-
volved in the control of autophagy by mTORC1. LC3-II is an
intermediate in the process of autophagy, not an endpoint. Thus, if
eEF2K regulated autophagy at multiple steps, LC3-II might well not
provide a good read-out for the level of autophagic ﬂux. We there-
fore used chloroquine (CQ), which inhibits autophagy downstream
of LC3 (and its lipidation). As expected, CQ increased the levels of
modiﬁed LC3-II (as it prevents its destruction during autophagy;
Fig. 3C) in MEFs treated with rapamycin (Rap) or AZD8055 (AZD).
Again, the absence of eEF2K did not prevent the modiﬁcation of
LC3; if anything, modiﬁcation was slightly greater in eEF2K−/−
cells treated with rapamycin and CQ than in the corresponding con-
trols (Fig. 3C, D). Thus, if anything, eEF2K acts to restrict LC3 modiﬁ-
cation in response to inhibition of mTORC1. Consistent with this, the
basal level of LC3 modiﬁcation was greater in eEF2K−/− cells than in
their wild-type counterparts [1]. Interestingly we also observe en-
hanced phosphorylation of S6; this might be due to increased au-
tophagic production of amino acids which activate mTORC1
signalling [36], although other explanations are possible.n the presence or absence of 1mM IPTG for 5 days to induce the knockdown of eEF2K. Cells
r MG132 (10 μM) for 16 h. Cells were then lysed and samples containing equal amounts of
lane show quantitation of the signal for LC3II, corrected for the actin signal frommultiple
t treatment=1; n=3). (B) A549 cellswere cultured as in (A) to induce eEF2Kknockdown.
dia in the presence or absence of AZD8055 (1 μM) for 16 h, in the presence of leupeptin and
panel). Values given below show the quantitation of data frommultiple experiments as in
SEM (control cells without treatment =1; n = 3). Values given below each lane show
s as in (B) expressed as P-eEF2 normalized to eEF2, mean ± SEM (control cells without
by confocal microscopy and the rate of autophagosome–lysosome fusion was measured
bar = 20 μm. (D) Data quantiﬁcation of C, data are presented as means ± SEM. (n = 5)
re treated with AZD8055 and BafA1 as described in A, cell lysates were collected at T0, 1
f the signal for LC3II, corrected for the LC3I signal from multiple experiments as in
n = 3).
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Fig. 4. eEF2K aids the survival of TSC2−/− cells under glucose-starved conditions. (A) TSC2−/−MEFsweremaintained inmediumcontaining (control) or lacking glucose (−Glc) for 24 h in
thepresenceof rapamycin (20nM) and compounds JAN-613 (less active) or JAN-384 (highly active) (each at 3 μM). Cellswere then lysed and samples containing equal amounts of protein
were analysed bywestern blot using the indicated antibodies. Values given below each lane show quantitation of the signal for LC3II, corrected for the actin signal or P-eEF2, corrected for
the eEF2 signal frommultiple experiments as in (A), mean ± SEM (control cells without treatment =1; n= 3). (B) Cells were treated for 48 h as described in (A), except that they were
processed for caspase 3/7 assay.
291C.E.J. Moore et al. / Cellular Signalling 28 (2016) 284–2933.5. eEF2K contributes to the cytoprotective effect of rapamycin in cells with
hyperactive mTORC1 signalling
Choo et al. [37] previously reported that cells lacking TSC2, a nega-
tive regulator ofmTORC1 signalling, are particularly sensitive to glucose
starvation and that rapamycin was cytoprotective under such condi-
tions, acting by slowing down (energy-requiring) anabolic processes.
Since eEF2K controls a major energy-consuming anabolic process (pro-
tein synthesis), is negatively regulated bymTORC1, and is thus stimulat-
ed by treatment of cells with rapamycin [38], we asked whether eEF2K
played a role in these effects.
As expected, eEF2 phosphorylationwas low in TSC2−/− cells (Fig. 4A).
When these cells were starved of glucose, eEF2 phosphorylation
remained low, presumably due to the high level of mTORC1 signalling.
We previously reported that in TSC2−/− cells that mTORC1 activation
blocked the transcription of eEF2K [39]. The addition of rapamycin re-
verses this effect as a result the total levels of eEF2K protein increase.
Therefore, the addition of rapamycin to cells starved of glucose caused a
large increase in eEF2 phosphorylation (Fig. 4A). A more recently-
developed, highly-active eEF2K inhibitor from Janssen Pharmaceutica
NV, JAN-384, almost completely prevented this increase in eEF2 phos-
phorylation,while a closely-related less active analogue, JAN-613, did not.
To assess cell viability, we measured caspase 3/7 activity (Fig. 4B).
Judged by both criteria, glucose starvation adversely affected the
TSC2−/− cells, and this effect was fully (Fig. 4B) countered by
rapamycin, although in our hands the effects were consistently smaller
in magnitude than those reported by Choo et al. [37], who starved their
cells for longer (60 h). In the case of caspase activity, rapamycinFig. 3. Role of eEF2K in autophagy inmouse embryonic ﬁbroblasts (MEFs).Wildtype (WT) and
2-deoxyglucose (2DG) or in medium lacking glucose (−Glc) for 24 h. Cells were then lysed an
indicated antibodies. (B) Quantitation of data from multiple experiments as in (A) expressed
(C) Wild-type (WT) and eEF2K−/− (KO) MEFs were treated, where indicated, with rapamyc
lysed and samples containing equal amounts of protein were analysed by western blot usi
(C) expressed as LC3II normalized to actin, mean ± SEM (control cells without treatment =1;decreased this in control conditions too. Importantly, the protective ef-
fect of rapamycin was lost when cells were treated with the highly ac-
tive eEF2K inhibitor JAN-384, while JAN-613 had no effect (Fig. 4B).
The differing effects of JAN-613 and JAN-384 on both eEF2 phos-
phorylation and cell viability markers indicates that much, perhaps
most, of the protective effect of rapamycin is mediated through eEF2K
and thus presumably via inhibition of protein synthesis. The eEF2K-
mediated inhibition of protein synthesis likely plays a major role in
the ability of rapamycin to bring energy demand more closely into
line with energy supply under glucose-starved conditions [37]. Several
earlier studies have suggested that eEF2K positively regulates autopha-
gy in other cell types [16–18,40] where mTORC1 signalling is not
hyperactivated. This effect might potentially contribute to the
cytoprotective effects of rapamycin in glucose-starved TSC2−/− cells.
However, Choo et al. [37], using similar cells and protocols as those
we have used, excluded a requirement for autophagy in the
cytoprotection afforded by rapamycin. Glucose starvation did increase
the modiﬁcation of LC3 in TSC2−/−MEFs, but this was not signiﬁcantly
affected by inhibiting eEF2K (Fig. 4A). Thus, it appears that the
cytoprotective effect of eEF2K in this setting is not linked to regulation
of autophagy.
4. Discussion
The present data add further support to the concept that eEF2K plays
an important role in enabling cancer cells to survive glucose starvation,
in particular by extending earlier work to show that (i) pharmacological
inhibition of eEF2K, like knocking down its expression, impairs theeEF2K−/− (KO)MEFs were treated, where indicated, withMK2206 (MK) (5 μM) or 10mM
d samples containing equal amounts of protein were analysed by western blot using the
as LC3II normalized to actin, mean ± SEM (control cells without treatment =1; n = 3).
in (50 nM) or AZD8055 (0.5 μM) and/or chloroquine (10 μM) for 24 h. Cells were then
ng the indicated antibodies. (D) Quantitation of data from multiple experiments as in
n = 3).
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cancer cell types other than those previously tested (whichweremainly
glioma, see e.g., [1]) and (iii) that restoring inhibition of elongation in
cells where eEF2K has been inhibited ‘rescues’ them from cell death, in-
dicating that eEF2K protects cells by inhibiting protein synthesis. This is
consistent with eEF2Ks ability to phosphorylate and inhibit its only
known substrate, eEF2.
mTORC1 signalling, a negative regulator of eEF2K, is activated in a
high proportion of cancers, leading to the idea that inhibiting
mTORC1, using rapamycin or related compounds, may be an effective
anti-cancer therapy. However, Choo et al. [37] showed that rapamycin
actually promoted the survival of cells in which mTORC1 is hyper-
activated (TSC2-null cells)when they are starved of glucose. Rapamycin
promotes activation of eEF2K by blocking mTORC1 signalling. Here we
show that inhibiting eEF2K substantially reverses the pro-survival effect
of rapamycin in TSC2-null cells. This implies that eEF2K makes an
important contribution to the pro-survival effects of rapamycin in this
setting and that inhibition of eEF2K may be particularly effective in in-
ducing the death of cells with hyperactive mTORC1 under conditions
of nutrient shortage. These data lend further support to the concept
that inhibiting eEF2K activity is likely useful in tackling solid tumours
[1,41].
Previous studies, many of them in glioma cells, have indicated
that eEF2K is a positive regulator of autophagy, a process which can
aid the survival of nutrient-starved cells [20,42]. Given that
mTORC1 signalling negatively regulates both eEF2K and autophagy,
these data were of considerable interest; for example, they sug-
gested that eEF2K might provide a link between mTORC1 and the
control of autophagy. However, in the cell lines we have studied,
we ﬁnd no evidence that eEF2K positively regulates autophagy. In
fact, in some cases there was a trend for the extent of LC3 modiﬁca-
tion, a key step in autophagy, to be greater in settings where eEF2K
has been inhibited or knocked down, although the differences were
modest. Consistent with our ﬁndings, a very recent study [43] re-
ported that silencing of eEF2K actually promoted autophagy, at
least under basal conditions, suggesting a negative link between
eEF2K and autophagy in this situation.
Several studies have shown that mTORC1 can regulate ULK1 and
other components that regulate autophagy (reviewed, [9]). It seems
likely that these signalling links, rather than eEF2K, couple nutrient star-
vation and inhibited mTORC1 signalling to the induction of autophagy.
In addition, other signalling links, e.g., via AMPK, can also couple nutri-
ent deprivation to activation of autophagy [14].
Our data show that inhibiting protein synthesis rescues the impair-
ment in cell survival seen in nutrient-deprived cells when eEF2K is
inhibited. eEF2K has only one known substrate, eEF2, which is required
for the energy-intensive process of translation elongation. Thus, the log-
ical explanation for these observations is that activation of eEF2K con-
tributes to cell survival by phosphorylating (and inhibiting) eEF2,
thereby decreasing the demands of protein synthesis for energy and
thus metabolic fuels such as glucose. These data are important for un-
derstanding the role of eEF2K in cancer cell biology and its relevance
for cancer therapy.Acknowledgments
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